More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC

Alberto Zanetto, Elena Campello, Cristiana Bulato, Sabrina Gavasso, Graziella Saggiorato, Sarah Shalaby, Luca Spiezia, Umberto Cillo, Fabio Farinati, Francesco Paolo Russo, Patrizia Burra, Marco Senzolo, Paolo Simioni – 15 August 2021 – In patients with cirrhosis, particularly those with hepatocellular carcinoma (HCC), hypercoagulability may be associated with purported increased risks of portal vein thrombosis and cirrhosis progression.

Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial

Lai Wei, Tingting Zhao, Ji Zhang, Qing Mao, Guozhong Gong, Yongtao Sun, Yongping Chen, Maorong Wang, Deming Tan, Zuojiong Gong, Baosen Li, Junqi Niu, Shuchen Li, Huanyu Gong, Liyun Zou, Wei Zhou, Zhengcai Jia, Yan Tang, Lei Fei, Yang Hu, Xiaoyun Shang, Junfeng Han, Bei Zhang, Yuzhang Wu – 14 August 2021

Hepatitis E virus infection activates NOD‐like receptor family pyrin domain‐containing 3 inflammasome antagonizing interferon response but therapeutically targetable

Yang Li, Peifa Yu, Amy L. Kessler, Jingyi Shu, Xiaoyan Liu, Zhaochao Liang, Jiaye Liu, Yunlong Li, Pengfei Li, Ling Wang, Yining Wang, Zhongren Ma, Aixia Liu, Ling Wang, Marco J. Bruno, Robert A. Man, Maikel P. Peppelenbosch, Sonja I. Buschow, Lin Wang, Yijin Wang, Qiuwei Pan – 14 August 2021

Reply

Cynthia Wat, Edward Gane, Man‐Fung Yuen, Vedran Pavlovic, Henrik Mueller, Ben‐Fillippo Krippendorff, Joseph F. Grippo, Soren Ottosen – 14 August 2021

Subscribe to